Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2025 Financial Results

Core Business Highlights - Sangamo Therapeutics announced positive topline results from the registrational Phase 1/2 STAAR study for isaralgagene civaparvovec (ST-920) in Fabry disease, showing a mean annualized estimated glomerular filtration rate (eGFR) slope of 1.965 mL/min/1.73m²/year at 52 weeks across all 32 patients dosed [6][4] - The FDA has agreed that the eGFR slope will serve as the primary basis for approval under the Accelerated Approval pathway [6] - The company raised approximately $21 million in net proceeds from an underwritten registered equity offering [5] Financial Performance - For Q2 2025, Sangamo reported revenues of $18.3 million, a significant increase from $0.3 million in Q2 2024, primarily due to an upfront license payment from Eli Lilly [8] - The consolidated net loss for Q2 2025 was $20.0 million, or $0.08 per share, compared to a net loss of $36.1 million, or $0.18 per share, for the same period in 2024 [7] - Total operating expenses for Q2 2025 were $36.2 million, a decrease from $37.4 million in Q2 2024, driven by cost reductions from strategic realignment [11][10] Pipeline Developments - The first clinical site for the Phase 1/2 STAND study in chronic neuropathic pain has been initiated, with the first patient expected to be dosed in fall 2025 and preliminary efficacy data anticipated in late 2026 [2][4] - Sangamo plans to present additional clinical data at the 15th International Congress of Inborn Errors of Metabolism in September 2025 [9] - The company is advancing preparations for a Clinical Trial Application (CTA) submission for ST-506, an investigational treatment for prion disease, expected as early as mid-2026 [9] Cash Position and Financial Guidance - As of June 30, 2025, cash and cash equivalents were $38.3 million, down from $41.9 million at the end of 2024, but expected to fund operations into Q4 2025 [12] - The company reiterated its financial guidance for 2025, expecting total operating expenses in the range of approximately $135 million to $155 million on a GAAP basis [13][14]